TALVEY®▼ (talquetamab) and DARZALEX® (daratumumab) subcutaneous (SC) formulation-based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
Updated data show 100 percent overall response rate, with 56 percent of patients achieving complete response or better with weekly…
